Back to Search
Start Over
Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming — Australian Snakebite Project (ASP-14)
- Source :
- PLoS ONE, PLoS ONE, Vol 7, Iss 12, p e53188 (2012)
- Publication Year :
- 2012
- Publisher :
- Public Library of Science (PLoS), 2012.
-
Abstract
- BACKGROUND: Snakebite is a global health issue and treatment with antivenom continues to be problematic. Brown snakes (genus Pseudonaja) are the most medically important group of Australian snakes and there is controversy over the dose of brown snake antivenom. We aimed to investigate the clinical and laboratory features of definite brown snake (Pseudonaja spp.) envenoming, and determine the dose of antivenom required. METHODS AND FINDING: This was a prospective observational study of definite brown snake envenoming from the Australian Snakebite Project (ASP) based on snake identification or specific enzyme immunoassay for Pseudonaja venom. From January 2004 to January 2012 there were 149 definite brown snake bites [median age 42 y (2-81 y); 100 males]. Systemic envenoming occurred in 136 (88%) cases. All envenomed patients developed venom induced consumption coagulopathy (VICC), with complete VICC in 109 (80%) and partial VICC in 27 (20%). Systemic symptoms occurred in 61 (45%) and mild neurotoxicity in 2 (1%). Myotoxicity did not occur. Severe envenoming occurred in 51 patients (38%) and was characterised by collapse or hypotension (37), thrombotic microangiopathy (15), major haemorrhage (5), cardiac arrest (7) and death (6). The median peak venom concentration in 118 envenomed patients was 1.6 ng/mL (Range: 0.15-210 ng/mL). The median initial antivenom dose was 2 vials (Range: 1-40) in 128 patients receiving antivenom. There was no difference in INR recovery or clinical outcome between patients receiving one or more than one vial of antivenom. Free venom was not detected in 112/115 patients post-antivenom with only low concentrations (0.4 to 0.9 ng/ml) in three patients. CONCLUSIONS: Envenoming by brown snakes causes VICC and over a third of patients had serious complications including major haemorrhage, collapse and microangiopathy. The results of this study support accumulating evidence that giving more than one vial of antivenom is unnecessary in brown snake envenoming.
- Subjects :
- Male
Antivenom
lcsh:Medicine
Snake Bites
Poison control
Toxicology
Pseudonaja textilis
0302 clinical medicine
Immunotoxicology
Toxin Binding
Elapidae
Prospective Studies
030212 general & internal medicine
lcsh:Science
Child
Aged, 80 and over
0303 health sciences
Multidisciplinary
biology
Allergy and Hypersensitivity
Antivenins
Clinical Pharmacology
Hematology
Middle Aged
3. Good health
Child, Preschool
Medicine
Female
Research Article
Adult
Drugs and Devices
Adolescent
Coagulation Factor Deficiences
Immunology
Immunoglobulins
complex mixtures
03 medical and health sciences
medicine
Animals
Humans
Dosing
Envenomation
Biology
Pseudonaja
Aged
030304 developmental biology
Elapid Venoms
Coagulation Disorders
Herpetology
business.industry
lcsh:R
Australia
biology.organism_classification
medicine.disease
Snake bites
Brown snake
lcsh:Q
business
Zoology
Classics
Subjects
Details
- ISSN :
- 19326203
- Volume :
- 7
- Database :
- OpenAIRE
- Journal :
- PLoS ONE
- Accession number :
- edsair.doi.dedup.....65431a748abb3f43c648b4116cf0f797